Lv1
60 积分 2023-09-18 加入
Examination of Noncanonical Kinase Hinge Binders Leads to Thiadiazoles as Potent IRAK4 Inhibitors
7天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
21天前
已完结
Cetuximab in advanced non-small-cell lung cancer (NSCLC)
22天前
已完结
Active-target liposomal drug shows significant atherosclerotic plaque regression effect: a proof-of-concept phase 1b/2a clinical trial
1个月前
已完结
Efficacy and Tolerability of Gefapixant for Treatment of Refractory or Unexplained Chronic Cough
2个月前
已完结
Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial
2个月前
已完结
P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study
3个月前
已完结
Assessing the risk of drug crystallization in vivo
3个月前
已完结
Discovery of Edecesertib (GS-5718): A Potent, Selective Inhibitor of IRAK4
4个月前
已完结
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials
4个月前
已完结
皖公网安备34019202002308
